irofulven has been researched along with Breast Cancer in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 3 (75.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fitzsimmons, TD; Hammond, LA; Harrison, JM; Melendez, RF; Rowinsky, EK | 1 |
Calvo, F; Cvitkovic, E; Koeppel, F; Laar, ES; Larsen, AK; Lokiec, F; Poindessous, V; Raymond, E; Serova, M; Waters, SJ | 1 |
Chen, SF; Dexter, DL; Kelner, MJ; MacDonald, JR; Mangold, GL; McMorris, TC; Muscoplat, CC; Von Hoff, DD | 1 |
Herzig, MC; Johnson, AE; Liang, H; Woynarowska, B; Woynarowski, JM | 1 |
4 other study(ies) available for irofulven and Breast Cancer
Article | Year |
---|---|
Acute retinal toxicity from the novel anti-tumor agent, Irofulven.
Topics: Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Electroretinography; Evoked Potentials, Visual; Female; Humans; Middle Aged; Retina; Retinal Diseases; Sesquiterpenes; Visual Fields | 2004 |
Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Colonic Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Genes, p53; HT29 Cells; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Sesquiterpenes; Tetrazolium Salts; Thiazoles | 2006 |
Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.
Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Drug Screening Assays, Antitumor; Female; HT29 Cells; Humans; Leukemia P388; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Nude; Sesquiterpenes; Transplantation, Heterologous | 1997 |
Irofulven induces apoptosis in breast cancer cells regardless of caspase-3 status.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Breast Neoplasms; Caspase 3; Caspases; Cell Survival; DNA Fragmentation; Enzyme Activation; Female; Humans; Kinetics; Sesquiterpenes; Tumor Cells, Cultured | 2002 |